Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. MU
6. USO
7. APGE
8. ABBV
9. MSFT
10. IBM

Go back to Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress

Karyopharm Therapeutics (KPTI) Reports In-Line Q4 EPS, Revenues Beat

February 11, 2021 7:12 AM EST

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.59), in-line with the analyst estimate of ($0.59). Revenue for the quarter came in at $35 million versus the consensus estimate of $29.37 million.

"Karyopharm made substantial progress in 2020 towards its mission of improving the lives of patients with cancer, marked by the FDA approval of XPOVIO in two additional... More